On August 1, 2016 Progenitor Life Sciences LLC, developer of proprietary technologies for producing induced-pluripotent stem cells (iPSCs) and natural killer (NK) cells from adult donors for use as universally compatible ‘off-the-shelf’ cellular immuno-therapies, reported it has retained Maxim Group LLC as its exclusive financial advisor (Press release, Progenitor Cell Therapy, AUG 1, 2016, View Source [SID:1234514165]). Maxim will assist the Company in identifying and negotiating partnerships that could result in a wide range of strategic transactions. Schedule your 30 min Free 1stOncology Demo! Progenitor CEO Gary R. Sams stated, "Our approach using proprietary iPSC and immunocompatibility technologies to generate universal donor/recipient-compatible chimeric antigen receptor T cells and NK cells (CAR-T and CAR-NK cells) is truly unique and efficient. Our technologies provide developers of CAR therapies a competitive advantage by enabling rapid, high throughput production and functional screening of CAR-expressing immune cells. Because our cell lines are generated with non-disruptive DNA insertion technology, they are more reliable and offer a potentially greater margin of safety for use in cell-based therapies. The agreement with Maxim Group will enhance our ability to establish strategic partnerships and collaborations with companies in the immuno-oncology sector that would benefit significantly from our unique capabilities."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!